GlassScriptPhysician profile
Yuliya White
NPI 1285305649
$2,443.15
in general payments reported to CMS, 2019-2025
22 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $317 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.13 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $372.02 | 2024-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $262.02 | 2024-2025 | Korlym |
| Lilly USA, LLC | $204.13 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Merz North America, INC. | $165.37 | 2024 | |
| Pfizer INC. | $142.21 | 2025 | |
| Abbvie INC. | $120.23 | 2025 | |
| Dexcom, INC. | $117.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $108.28 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $51.17 | 2025 | |
| Exact Sciences Corporation | $43.55 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $39.21 | 2025 | Tepezza, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $30.03 | 2025 | Voquezna |
| Recordati_rare_diseases_inc. | $29.80 | 2025 | Isturisa |
| Tandem Diabetes Care, INC. | $25.10 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.00 | 2025 | Veozah |
| Mannkind Corporation | $22.43 | 2025 | |
| Chiesi USA, INC. | $22.42 | 2025 | Mycapssa |
| Xeris Pharmaceuticals, INC. | $21.55 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $21.03 | 2025 | Trelegy Ellipta |
| Sequel Med Tech, LLC | $15.23 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $14.24 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuliya White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.